stockrow
Friday 6 November 2026
Export NAMS’s income statement to Excel — free account
NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.
- Revenue
- +5,406.9%
- EPS
- +77.1%
- Free cash flow
- −21.8%
Quarter to September 2026, against a year earlier
19.02
0.13
+0.69%
Follow NAMS
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 3 | 3 |
+8 more TTM periods Free account |
| (30.16%) | (36.81%) | (29.49%) | (28.29%) | ||
| (27.79%) | (34.16%) | (27.43%) | (24.95%) | ||
ROIC |
(23.13%) | 0.00% | (484.09%) | (307.51%) | |
Return on Tangible Assets |
(33.28%) | (44.24%) | (36.00%) | (34.53%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.22) | (1.16) | (1.17) | (1.25) | |
Free Cash Flow |
(150.86) | (143.72) | (142.19) | (148.03) | |
Capital Expenditures |
(0.39) | (0.26) | (0.27) | (0.25) | |
| Other line items | |||||
Cash ROIC |
(23.92%) | (11.35%) | (10.92%) | (11.21%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
607.75% | 2,095.87% | 598.67% | 630.28% | |
Selling, General and Administrative Expense of Revenue |
392.32% | 1,436.33% | 454.92% | 472.62% | |
Share Based Compensation of Revenue |
242.60% | 918.64% | 275.71% | 264.08% | |
Operating CF/Net income |
0.73 | 0.55 | 0.67 | 0.73 | |
Depreciation/Fixed assets |
0.45 | 0.59 | 0.61 | 0.57 | |
Capex/Depreciation |
(1.60) | (1.07) | (1.17) | (1.12) | |
Revenue per Share |
0.21 | 0.06 | 0.19 | 0.19 | |
Operating CF per Share |
(1.21) | (1.16) | (1.17) | (1.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.04 | 0.01 | 0.01 |
Columns are period end dates · fundamentals updated 4 Nov 2026